By Dave Levitan
An analysis of the phase III SOLO1 trial found no new safety signals when the PARP inhibitor olaparib was given as maintenance therapy for women with newly diagnosed advanced ovarian cancer and a BRCA mutation. Nausea, fatigue, … Read more
By Dave Levitan
Maintenance therapy with the PARP inhibitor rucaparib offered improved post-progression outcomes in a phase III trial of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who were in a complete or partial response to … Read more
Patients with BRCA-mutated, platinum-sensitive relapsed ovarian cancer derived significant clinical benefit from treatment with olaparib monotherapy compared with treatment of physician’s choice, according to the results of the SOLO3 trial, a US Food and Drug Administration … Read more
By Leah Lawrence
Single-agent carboplatin conferred significantly worse survival outcomes in vulnerable, elderly patients with stage III/IV epithelial ovarian cancer compared with weekly or every 3 weeks carboplatin/paclitaxel, according to results of the EWOC-1 trial (abstract 5508), which … Read more
By Ian Ingram
Benefit seen across all subgroups for patients with platinum-sensitive disease.
Ovarian cancer patients with recurrent, platinum-sensitive disease experienced a longer interval without disease progression when bevacizumab (Avastin) was added to niraparib (Zejula), a phase II study found.… Read more
A gynecologic oncologist at the Stephenson Cancer Center at OU Medicine was a national leader of a newly published research study that reveals good news for women with ovarian cancer—longer survival times plus a treatment option that causes fewer difficult … Read more
By Charles Bankhead
No PFS or OS benefit, more toxicity with IP verses IV regimens
Final results of a highly anticipated randomized trial failed to show a survival benefit with intraperitoneal (IP) chemotherapy in patients with newly diagnosed advanced ovarian … Read more
By Dave Levitan
Niraparib showed promising and clinically relevant activity as therapy for heavily pretreated patients with ovarian cancer, according to a new phase II study. This was particularly true among women with homologous recombination deficiency (HRD)-positive tumors.
“Although most … Read more
IMV Inc., a clinical stage immuno-oncology corporation, today announced preliminary data from the phase 2 cohort of the DECIDE clinical study. Six patients receiving DPX-Survivac monotherapy with intermittent low-dose cyclophosphamide (mCPA) have reached the first CT scan assessment with key … Read more
By Christina Bennett, MS
Rucaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, was effective as a maintenance therapy across all age groups of patients with recurrent ovarian cancer, according to the results of a post-hoc exploratory analysis of ARIEL3 presented at … Read more
By Ian Ingram
Trial stopped for futility, but 13-month OS improvement seen in patients with BRCA mutations.
Trabectedin (Yondelis) plus pegylated liposomal doxorubicin (PLD) failed to improve survival in a phase III trial of third-line ovarian cancer, but a survival … Read more
By Ian Ingram
But showed promise in PD-L1-positive group.
Adding avelumab (Bavencio) to pegylated liposomal doxorubicin (PLD) failed to improve survival outcomes for patients with platinum-resistant or refractory ovarian cancer in a phase III trial reported here.
In the intent-to-treat … Read more
By Ian Ingram
Clinical benefit rate tops 90% in pair of single-center studies.
Two early trials of novel combinations showed promising clinical activity in gynecologic cancers at a late-breaking abstract session at the Society of Gynecologic Oncology (SGO) meeting here.… Read more
By Christina Bennett, MS
Pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide showed clinical activity in patients with recurrent epithelial ovarian cancer, according to the results of an open-label phase II trial (LBA4) presented at the 2019 Society of … Read more
By Kristie L. Kahl
Lenvatinib (Lenvima) in combination with weekly paclitaxel induced activity among those with recurrent endometrial and platinum-resistant epithelial ovarian cancer, resulting in a 65% overall response rate (ORR), according to results from a phase I study presented … Read more
The treatment offers long-lasting anti-tumor immunity.
The addition of a dendritic cell immunotherapy to chemotherapy has been found to prolong overall survival significantly in patients with recurrent ovarian cancer. The combination of chemotherapy + immunotherapy corresponded to 73% survival after … Read more
By Krista Conger
Over the years, I’ve written quite a bit about a protein called CD47 that is found on the surface of many types of cancer cells, as well as on aging red blood cells.
In 2009, researchers in … Read more
US-based biotechnology company ImmunoGen has reported negative top-line results from the Phase III FORWARD I ovarian cancer trial of mirvetuximab soravtansine.
The study failed to meet its primary endpoint of progression-free survival (PFS). Mirvetuximab soravtansine is an antibody-drug conjugate (ADC) … Read more
By Milton Packer, MD
Most observers do not understand what the academic leaders of a clinical trial really do. To many, the steering committee simply takes its marching orders from industry sponsors. Some believe that every trial is designed by … Read more
By Jessica Skarzynski
For some time now, paclitaxel has been considered standard of care in the treatment of patients with platinum-resistant ovarian cancer; however, recent research has shown the addition of the investigational drug alisertib to a paclitaxel regimen demonstrated … Read more
